BioPharmSignal logoBioPharmSignal

Biotech News

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Black Diamond Therapeutics (BDTX)Black Diamond TherapeuticsClinical readout

Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will

Related news

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

CGEMCullinan Therapeutics, Inc.2026-09-10 17:00 EST

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

FATEFate Therapeutics2026-09-25 11:00 EST

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

CGEMCullinan Therapeutics, Inc.2026-09-14 11:00 EST

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

INBXInhibrx2026-09-04 20:00 EST

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

BDTXBlack Diamond Therapeutics2026-09-02 20:01 EST

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

BDTXBlack Diamond Therapeutics2026-08-05 20:01 EST

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Black Diamond Therapeutics

Mutation-Family Precision Oncology Black Diamond Therapeutics develops MasterKey therapies designed to inhibit families of oncogenic mutations with a single small molecule. Silevertinib Silevertinib is a brain-penetrant kinase inhibitor targeting canonical and noncanonical EGFR mutations, including alterations that are difficult to...

Recent company news

BDTXBlack Diamond Therapeutics2026-09-02 20:01 EST

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

BDTXBlack Diamond Therapeutics2026-08-05 20:01 EST

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-05-22 12:00 EST

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

BDTXBlack Diamond Therapeutics2026-05-21 21:14 EST

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

BDTXBlack Diamond Therapeutics2026-05-19 12:00 EST

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Stock data

Close
1.89 USD
Market cap
124.92M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States